CN104093418A - 金黄色葡萄球菌抗原的含佐剂制剂 - Google Patents

金黄色葡萄球菌抗原的含佐剂制剂 Download PDF

Info

Publication number
CN104093418A
CN104093418A CN201280053918.1A CN201280053918A CN104093418A CN 104093418 A CN104093418 A CN 104093418A CN 201280053918 A CN201280053918 A CN 201280053918A CN 104093418 A CN104093418 A CN 104093418A
Authority
CN
China
Prior art keywords
seq
composition
antigen
tlr agonist
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280053918.1A
Other languages
English (en)
Chinese (zh)
Inventor
F·巴格诺利
B·宝德纳
S·布法力
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN104093418A publication Critical patent/CN104093418A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN201280053918.1A 2011-09-01 2012-08-31 金黄色葡萄球菌抗原的含佐剂制剂 Pending CN104093418A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161530162P 2011-09-01 2011-09-01
US61/530,162 2011-09-01
US201261607999P 2012-03-07 2012-03-07
US61/607,999 2012-03-07
PCT/EP2012/067032 WO2013030378A1 (en) 2011-09-01 2012-08-31 Adjuvanted formulations of staphylococcus aureus antigens

Publications (1)

Publication Number Publication Date
CN104093418A true CN104093418A (zh) 2014-10-08

Family

ID=46763095

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280053918.1A Pending CN104093418A (zh) 2011-09-01 2012-08-31 金黄色葡萄球菌抗原的含佐剂制剂

Country Status (14)

Country Link
US (1) US20140363461A1 (enExample)
EP (1) EP2763695A1 (enExample)
JP (1) JP2014525429A (enExample)
KR (1) KR20140066212A (enExample)
CN (1) CN104093418A (enExample)
AU (1) AU2012300765A1 (enExample)
BR (1) BR112014004782A2 (enExample)
CA (1) CA2847204A1 (enExample)
IL (1) IL231104A0 (enExample)
IN (1) IN2014CN02152A (enExample)
MX (1) MX2014002363A (enExample)
RU (1) RU2014112343A (enExample)
SG (1) SG11201400210RA (enExample)
WO (1) WO2013030378A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105646681A (zh) * 2016-01-21 2016-06-08 浙江海隆生物科技有限公司 一种奶牛金黄色葡萄球菌α-溶血素亚单位疫苗的制备方法及应用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859489B2 (en) * 2009-04-03 2014-10-14 Momenta Pharmaceuticals, Inc. Water-mediated control of depolymerization step of glatiramer acetate synthesis
BR112012004806B8 (pt) 2009-09-02 2022-10-04 Novartis Ag composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
ES2458355T3 (es) 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
WO2012109167A1 (en) 2011-02-08 2012-08-16 Integrated Biotherapeutics, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
RU2014112343A (ru) * 2011-09-01 2015-10-10 Новартис Аг Оставы антигенов staphylococcus aureus, содержащие адъюванты
HUE030175T2 (en) * 2012-03-07 2017-04-28 Glaxosmithkline Biologicals Sa Arginine salt of TLR7 agonist
CN104159602B (zh) 2012-03-08 2017-10-24 葛兰素史密丝克莱恩生物有限公司 加强疫苗的含佐剂制剂
US20150191513A1 (en) * 2012-08-31 2015-07-09 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
EP2890387A1 (en) * 2012-08-31 2015-07-08 Novartis AG Stabilised proteins for immunising against staphylococcus aureus
HRP20191166T1 (hr) * 2012-08-31 2019-10-04 Glaxosmithkline Biologicals Sa Stabilizirani proteini, namijenjeni imuniziranju protiv bakterije staphylococcus aureus
BE1022359B1 (fr) * 2014-03-17 2016-03-25 Glaxosmithkline Biologicals Sa Immunisation contre des infections staphylococciques des os et des articulations
WO2015144691A1 (en) * 2014-03-26 2015-10-01 Glaxosmithkline Biologicals Sa Compositions for immunising against staphylococcus aureus
ES2769647T3 (es) * 2014-03-26 2020-06-26 Glaxosmithkline Biologicals Sa Antígenos estafilocócicos mutantes
ES2990113T3 (es) 2016-07-07 2024-11-28 The Board Of Trustees Of The Leland Stanfordjunior Univ Conjugados de adyuvantes de anticuerpos
AR111760A1 (es) * 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
CN113993549A (zh) 2019-03-15 2022-01-28 博尔特生物治疗药物有限公司 靶向her2的免疫缀合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010119343A2 (en) * 2009-04-14 2010-10-21 Novartis Ag Compositions for immunising against staphylococcus aureus
WO2011027222A2 (en) * 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE67769T1 (de) 1983-01-25 1991-10-15 Ciba Geigy Ag Neue peptidderivate.
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
SK117395A3 (en) 1993-03-23 1996-11-06 Smithkline Beecham Biolog Vaccine composition and manufacturing process thereof
KR20060065643A (ko) 2003-07-24 2006-06-14 머크 앤드 캄파니 인코포레이티드 스타필로코쿠스 아우레우스에 대한 방어 면역 반응을유도하는 폴리펩타이드
US20060188515A1 (en) 2003-07-24 2006-08-24 Anderson Annaliesa S Polypeptides for inducing a protective immune response against staphylococcus aureus
JP2007528217A (ja) 2004-02-18 2007-10-11 メルク　エンド　カムパニー　インコーポレーテッド スタヒロコッカス・アウレウスに対する防御免疫応答を誘導するためのポリペプチド
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
TW200801003A (en) 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
US20090192153A1 (en) 2005-09-22 2009-07-30 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
WO2007034916A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
TW200745114A (en) 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
EP1939202A4 (en) 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW COMPOUND OF ADENINE
JPWO2007034917A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規なアデニン化合物
WO2007093901A1 (en) 2006-02-17 2007-08-23 Pfizer Limited 3 -deazapurine derivatives as tlr7 modulators
KR20090019007A (ko) 2006-06-12 2009-02-24 나비 바이오파마슈티컬즈 스타필로코쿠스 감염증을 치료 및 예방하기 위한 알파-독소의 용도
WO2008004948A1 (en) 2006-07-05 2008-01-10 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of tlr7
AR061839A1 (es) 2006-07-07 2008-09-24 Gilead Sciences Inc Compuestos y composiciones farmaceuticas que activan selectivamente a receptores tipo toll 7(tlr7), y uso de los mismos como agentes antivirales
WO2008152447A2 (en) 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
HRP20110115T1 (hr) 2007-02-19 2011-03-31 Glaxosmithkline Llc Derivati purina kao imunomodulatori
PE20081887A1 (es) 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Nuevo compuesto de adenina
JP5400763B2 (ja) 2007-05-08 2014-01-29 アストラゼネカ・アクチエボラーグ 免疫調節特性を有するイミダゾキノリン類
JP2010535755A (ja) 2007-08-03 2010-11-25 ファイザー・リミテッド イミダゾピリジノン
WO2009029831A1 (en) 2007-08-31 2009-03-05 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
SI2268618T1 (sl) 2008-03-03 2015-09-30 Novartis Ag Spojine in sestavki kot modulatorji aktivnosti TLR
NZ588183A (en) 2008-03-24 2012-05-25 4Sc Discovery Gmbh Novel substituted imidazoquinolines
CA2732437C (en) 2008-08-01 2017-11-21 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
BRPI0923305B1 (pt) 2008-12-09 2019-01-22 Gilead Sciences Inc moduladores de receptores toll-like, seu uso e composição farmacêutica que os compreende
HUE036372T2 (hu) * 2009-06-22 2018-07-30 Wyeth Llc Staphylococcus aureus antigének immunogén készítményei
EP2453915B1 (en) 2009-07-16 2017-04-19 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Treatment of infections
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
TWI445708B (zh) * 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
CA2792938C (en) 2010-03-23 2018-07-31 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
ES2458355T3 (es) 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
US20140112950A1 (en) * 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
RU2014112343A (ru) * 2011-09-01 2015-10-10 Новартис Аг Оставы антигенов staphylococcus aureus, содержащие адъюванты
US20150132339A1 (en) * 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
CN104159602B (zh) * 2012-03-08 2017-10-24 葛兰素史密丝克莱恩生物有限公司 加强疫苗的含佐剂制剂
WO2013132043A1 (en) * 2012-03-08 2013-09-12 Novartis Ag Combination vaccines with tlr4 agonists
EP2890395A1 (en) * 2012-08-31 2015-07-08 Novartis AG Stabilised proteins for immunising against staphylococcus aureus
EP2890387A1 (en) * 2012-08-31 2015-07-08 Novartis AG Stabilised proteins for immunising against staphylococcus aureus
HRP20191166T1 (hr) * 2012-08-31 2019-10-04 Glaxosmithkline Biologicals Sa Stabilizirani proteini, namijenjeni imuniziranju protiv bakterije staphylococcus aureus
US20150191513A1 (en) * 2012-08-31 2015-07-09 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
BR112015005056A2 (pt) * 2012-09-06 2017-11-21 Novartis Ag vacinas de combinação com sorogrupo b meningococcus e d/t/p
GB201219420D0 (en) * 2012-10-29 2012-12-12 Novartis Ag Staphyloccal immunogens
EP2950819B1 (en) * 2013-02-01 2018-03-28 GlaxoSmithKline Biologicals SA Intradermal delivery of immunological compositions comprising toll-like receptor agonists
BE1022359B1 (fr) * 2014-03-17 2016-03-25 Glaxosmithkline Biologicals Sa Immunisation contre des infections staphylococciques des os et des articulations
WO2015144691A1 (en) * 2014-03-26 2015-10-01 Glaxosmithkline Biologicals Sa Compositions for immunising against staphylococcus aureus
ES2769647T3 (es) * 2014-03-26 2020-06-26 Glaxosmithkline Biologicals Sa Antígenos estafilocócicos mutantes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010119343A2 (en) * 2009-04-14 2010-10-21 Novartis Ag Compositions for immunising against staphylococcus aureus
WO2011027222A2 (en) * 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105646681A (zh) * 2016-01-21 2016-06-08 浙江海隆生物科技有限公司 一种奶牛金黄色葡萄球菌α-溶血素亚单位疫苗的制备方法及应用
CN105646681B (zh) * 2016-01-21 2021-07-16 浙江海隆生物科技有限公司 一种奶牛金黄色葡萄球菌α-溶血素亚单位疫苗的制备方法及应用

Also Published As

Publication number Publication date
SG11201400210RA (en) 2014-03-28
CA2847204A1 (en) 2013-03-07
RU2014112343A (ru) 2015-10-10
KR20140066212A (ko) 2014-05-30
EP2763695A1 (en) 2014-08-13
US20140363461A1 (en) 2014-12-11
IN2014CN02152A (enExample) 2015-09-04
MX2014002363A (es) 2014-04-14
AU2012300765A1 (en) 2014-03-13
BR112014004782A2 (pt) 2017-03-21
IL231104A0 (en) 2014-04-30
WO2013030378A1 (en) 2013-03-07
JP2014525429A (ja) 2014-09-29

Similar Documents

Publication Publication Date Title
CN104093418A (zh) 金黄色葡萄球菌抗原的含佐剂制剂
CN104159602B (zh) 加强疫苗的含佐剂制剂
JP4509554B2 (ja) アルミニウムアジュバントおよびヒスチジンを含むワクチン
CN1238696A (zh) 疫苗
AP431A (en) Influenza vaccine compositions.
KR102027429B1 (ko) 돌연변이 스태필로코쿠스 항원
CA3195971A1 (en) Neisseria meningitidis compositions and methods thereof
MX2015005306A (es) Nicotinamida como adyuvante.
JP2015521595A (ja) 血清群ｘ髄膜炎菌のためのワクチン
CN104582726A (zh) 狂犬病病毒免疫原的含佐剂制剂
JPH08506592A (ja) ３−ｏ−脱アシル化モノホスホリル脂質Ａ含有のインフルエンザワクチン組成物
KR20200053644A (ko) 보강제 제형 및 방법
CN112996538A (zh) 免疫原性组合物
CN101478987A (zh) 含有单克隆抗独特型抗ca-125抗体和铝的药物组合物
CN100384476C (zh) 含有作为疫苗辅药的磷酸铁的疫苗组合物
AU2004235815A1 (en) Vaccinating against infectious diseases using proteosomes
KR20240147612A (ko) 향상된 효능을 갖는 알루미늄계 애주번트를 제조하는 방법
WO2024199359A1 (zh) 包含环二核苷酸分子的脂质体佐剂系统及其制备方法
HK40011275A (en) Polyvalent streptococcus pneumoniae vaccine composition
PL174077B1 (pl) Szczepionka do ochrony przed zakażeniem lub leczeniem zakażeń Hepatitis B i heterologicznych chorób, zawierająca antygen powierzchniowy Hepatitis B (HBsAg)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20141008

RJ01 Rejection of invention patent application after publication